Component
1-Methyluric acid
Study-scoped entity; inspect species, exposure, model and limitations on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Allopurinol specifically and dose-dependently inhibited conversion of caffeine-derived 1-methylxanthine to 1-methyluric acid.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Two healthy nonsmokers; caffeine 5 mg/kg before/during allopurinol 300 or 600 mg/day.
- limitations
- Very small human mechanistic study; not proof that dietary molybdenum controls parent-caffeine clearance.
- nutrient_topic
- Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
- plain_language
- A later caffeine metabolite uses the xanthine-oxidoreductase pathway.
- primary_references
- Effect of allopurinol on caffeine disposition in man. · 1986 · https://pubmed.ncbi.nlm.nih.gov/3754760/ · DOI 10.1111/j.1365-2125.1986.tb05222.x
Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 228–234
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Two healthy nonsmokers; caffeine 5 mg/kg before/during allopurinol 300 or 600 mg/day. · source_derived_draft · unverified_draft
## caf-xor-product A later caffeine metabolite uses the xanthine-oxidoreductase pathway. Allopurinol specifically and dose-dependently inhibited conversion of caffeine-derived 1-methylxanthine to 1-methyluric acid. Model: Two healthy nonsmokers; caffeine 5 mg/kg before/during allopurinol 300 or 600 mg/day. Limitations: Very small human mechanistic study; not proof that dietary molybdenum controls parent-caffeine clearance. Evidence access: Primary abstract Effect of allopurinol on caffeine disposition in man. · 1986 · https://pubmed.ncbi.nlm.nih.gov/3754760/ · DOI 10.1111/j.1365-2125.1986.tb05222.x
Complete structured claim and evidence
Where it participates (unsigned role)
In 21 participants, allopurinol reduced urinary 1-methyluric-acid/1-methylxanthine to 15.9% of baseline.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- 200 mg caffeine tests during allopurinol 300 mg/day for eight days.
- limitations
- The ratio is a context-dependent probe, not a direct measurement of dietary molybdenum.
- nutrient_topic
- Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
- plain_language
- Blocking a downstream enzyme changed the metabolite pattern.
- primary_references
- Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. · 1999 · https://pubmed.ncbi.nlm.nih.gov/10027663/ · DOI 10.1007/s002280050569
Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 236–242
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · 200 mg caffeine tests during allopurinol 300 mg/day for eight days. · source_derived_draft · unverified_draft
## caf-xor-ratio Blocking a downstream enzyme changed the metabolite pattern. In 21 participants, allopurinol reduced urinary 1-methyluric-acid/1-methylxanthine to 15.9% of baseline. Model: 200 mg caffeine tests during allopurinol 300 mg/day for eight days. Limitations: The ratio is a context-dependent probe, not a direct measurement of dietary molybdenum. Evidence access: Primary abstract Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. · 1999 · https://pubmed.ncbi.nlm.nih.gov/10027663/ · DOI 10.1007/s002280050569
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.